Lin, J., Zhuang, Y., Hu, H., Huang, L., Yuan, J., Wei, X., Xu, M. (2025). Neoadjuvant chemoradiotherapy plus PD-1 inhibitor (tislelizumab) for high risk and MRF+ low locally advanced rectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e15644